C21orf91 overlapping transcript 1 (non-protein coding) (C21orf91-OT1)

C21orf91 overlapping transcript 1 (C21orf91-OT1) is a **long non-coding RNA (lncRNA)** located at chromosome 21 which does not encode a protein[2][4]. It is also referenced as D21S2089E or NCRNA00285. This transcript overlaps with the protein-coding gene C21orf91 in the genome. A representative biological function is its potential regulatory role in transcription: it has been shown to co-regulate the transcription of the C21orf91 gene in conjunction with the transcription factor JUND, impacting gene expression pathways that control cell proliferation and apoptosis in triple-negative breast cancer cell lines[5]. It operates through mechanisms such as acting with super-enhancer elements and influencing signal transduction pathways (e.g., PI3K-AKT-GSK3β-β-catenin, MAPK), but it is **not currently considered a direct therapeutic target, receptor, enzyme, transporter, or other classical "drug target" molecule** in pharmacology[5]. No drugs or chemical inhibitors are known to directly target this lncRNA, nor is it recognized as a clinical biomarker or associated with specific safety concerns at this time. **Additional details & clarifications:** - C21orf91-OT1 should not be confused with the protein-coding gene C21orf91, which is implicated in neural and glial cell development and is part of separate research involving Down syndrome and CNS development[6]. - The information available suggests C21orf91-OT1's role is mainly as a non-coding regulatory RNA, typically involved in gene expression regulation and potentially in tumor biology, but with little direct functional or therapeutic targeting at this time[2][5]. - Its current designation as a lncRNA means it belongs to "Other" in molecular classification schemes, not to any classical druggable protein families. - Because it is a transcript and not a protein, several of your requested categories (therapeutic target, interacting drugs, mechanism of drug action, biomarker, safety) return null. - There are no indications of misspelling or confusion in the naming, but its classification as a **therapeutic target** is not supported, and the entry is only relevant to research contexts.

Other names

D21S2089ENCRNA00285C21orf91-OT1C21orf91 overlapping transcript 1